Processa Pharmaceuticals

PCSA · NASDAQ

$1.79+$0.06 (+3.47%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $1.73

PCSA analyst rating

This isn't available right now. Refresh to try again.

The case for and against

Updated Feb 9, 2026

Bull case

Processa Pharmaceuticals Inc. is advancing its pipeline of Next Generation Chemotherapy (NGC) oncology drug products, with three key treatments—PCS6422, PCS3117, and PCS11T—positioned for future growth in the oncology market. The company's estimated net loss per share for full-year 2026 has improved, narrowing to $0.15 from $0.20, indicating potential operational efficiencies despite an increase in the outstanding share count. Additionally, the recent strategic investment and exploration of cryptocurrency treasury strategies signal a progressive approach to enhancing liquidity and ensuring financial stability, ultimately supporting the company's long-term objectives.

Bear case

Processa Pharmaceuticals Inc. is expected to face significant financial challenges, projecting a full-year 2025 net loss of $0.43 per share, indicating ongoing concerns about profitability. The company may encounter risks related to regulatory approvals, competition leading to lower-than-anticipated market penetration, and potential dilution impacts that could adversely affect shareholder value. Furthermore, the recent net loss of $0.25 per share aligns closely with previous forecasts, suggesting limited progress in improving its financial performance.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.